

o4Rule 3.19A.2

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Estia Health Limited
<b>ABN</b> 37 160 986 201

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ian Thorley
<b>Date of last notice</b>	29 November 2019

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Thorne Investments Pty Ltd ATF Thorley Superannuation Fund  Mr Thorley is a director of Thorne Investments Pty Ltd and a beneficiary of the superannuation fund.
<b>Date of change</b>	05 and 06 March 2020
<b>No. of securities held prior to change</b>	<b>Direct:</b> 33,513 fully paid ordinary shares 648,664 long term performance rights  <b>Indirect:</b> 51,505 fully paid ordinary shares
<b>Class</b>	1. Long term performance rights 2. Ordinary shares
<b>Number acquired</b>	<b>Direct:</b> 50,000 Ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	<b>Direct:</b> 81,430 Long term performance rights
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	28,169 - \$1.765743 per share 21,831 - \$1.739383 per share \$Nil per long term performance rights
<b>No. of securities held after change</b>	<b>Direct:</b> 83,513 fully paid ordinary shares 567,234 long term performance rights  <b>Indirect:</b> 51,505 fully paid ordinary shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Purchase of shares on market. Lapse of FY17 long term performance rights.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

Date of Notice: 09 March 2020

---

<sup>+</sup> See chapter 19 for defined terms.